Corvus Pharmaceuticals, Inc. - Common Stock (CRVS)

Corvus announced new interim data from its Phase 1 clinical trial evaluating Soquelitinib in patients with moderate to severe atopic dermatitis.

Corvus Pharmaceuticals, Inc.(NASDAQ:CRVS) on Thursday released new interim data from the Phase 1 clinical trial evaluating ...

Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session.

Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Wednesday. Let's explore the market movements and identify the stocks with significant gaps.

Research and development expenses in the reported quarter rose by $2 million, primarily due to increased spending on the soquelitinib clinical trial for T-cell lymphoma.

Corvus Pharmaceuticals shares interim Phase 1 trial data showing promising results for soquelitinib in treating moderate to severe atopic dermatitis.

U.S. stock futures climbed on Wednesday as Wall Street awaits the Fed's final interest rate decision and its monetary policy forecasts for 2025.